Bank of America Global Healthcare Conference 2025 September 23, 2025 4:50 AM EDTCompany ParticipantsPaul Hudson - CEO ...

Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...

The accelerated approval is for the treatment of adult and pediatric patients aged one year and older with diffuse midline glioma harboring an H3 K27M mutation and progressive disease following prior ...

A. Kybella has become a well-known option for treating fullness under the chin, and for the right patient, it can work quite well. Kybella is an injectable treatment that uses deoxycholic acid to ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery at a cash price that is up to 70% off the list price.

The weekly combination therapy is intended for adults with poor glucose control despite basal insulin or GLP-1 receptor agonist treatment.

Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered by a ...